- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00834847
Pravastatin Sodium 40 mg Tablets Food Challenge Study
A Relative Bioavailability Food Challenge Study of Pravastatin Sodium 40 mg Tablets
Study Overview
Detailed Description
Criteria for Evaluation: FDA Bioequivalence Criteria
Statistical Methods: FDA bioequivalence statistical methods
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M1R 5A3
- Pharma Medica Research Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Non-institutionalized subjects consisting of university students and members of the community at large.
- All subjects selected for this study will be males 18 to 45 (inclusive) years of age. Weight of the subjects shall not be more than 15% from the normal for height and body frame (Metropolitan Life, 1993, Height, Weight, Body Chart).
- Each subject shall be given a general physical examination within 21 days of initiation of the study. Such examination includes, but is not limited to, blood pressure, general observations, and history.
At the end of the study the subjects will have an exit evaluation consisting of interim history, global evaluation, and clinical laboratory measurements.
Adequate blood and urine samples should be obtained within 21 days before the beginning of the first period and at the end of the trial for clinical laboratory measurements.
Clinical laboratory measurements will include the following:
Hematology: hemoglobin, hematocrit, red blood cell count, platelets, and white blood cell count (with differential)
Clinical Chemistry: creatinine, BUN, glucose, SGOT, SGPT, bilirubin, and alkaline phosphatase
Urine Analysis: pH, specific gravity, protein, glucose, ketones, bilirubin, occult blood, and cells
HIV Screen: (pre-study only)
Hepatitis-B, C Screen: (pre-study only)
Drugs of Abuse Screen: (pre-study and at each dosing period check-in)
Subjects will be selected if all above are normal. Electrocardiograms of all participating subjects will be recorded before initiation of the study and filed with each subject's case report forms.
Exclusion Criteria
- Subjects with a history of chronic alcohol consumption, drug addiction, or serious gastrointestinal, renal, hepatic, or cardiovascular disease, tuberculosis, epilepsy, asthma, diabetes, psychosis or glaucoma will not be eligible for this study.
- Subjects whose clinical laboratory test values are greater than 20% outside the normal range may be retested. If the clinical values are outside the range on retesting the subject will not be eligible to participate in the study unless the clinical investigator deems the result to not be significant.
- Subjects who have a history of allergic responses to the class of drug being tested should be excluded from the study.
- Subjects who use tobacco in any form will not be eligible to participate in the study. Three months abstinence is required.
- All subjects will have urine samples assayed for the presence of drugs of abuse as part of the clinical laboratory screening procedures and at each dosing period check-in. Subjects found to have urine concentrations of any of the tested drugs will not be allowed to participate.
- Subjects should not have donated blood and/or plasma for at least thirty (30) days prior to the first dosing of the study.
- Subjects who have taken any investigational drug within thirty (30) days prior to the first dosing of the study will not be allowed to participate.
- Subjects who have been exposed to known hepatic enzyme inducing or inhibiting agents within (30) days prior to dosing will not be allowed to participate.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Pravastatin fast
Test product under fasting conditions dosed in first period followed by either test or reference product dosed under fed conditions in second and third periods
|
40 mg tablet
|
EXPERIMENTAL: Pravastatin
Test product under fed conditions dosed in first period followed by either test product dosed under fasting conditions or reference product dosed under fed conditions in second and third periods
|
40 mg tablet
|
ACTIVE_COMPARATOR: Pravachol®
Reference product under fed conditions dosed in first period followed by test product dosed under either fed or fasted conditions in second and third periods
|
40 mg Tablet
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax - Maximum Observed Concentration
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
AUC0-t - Area under the concentration-time curve from time zero to time of last non-zero concentration (per participant)
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Cmax - Comparison of the difference in plasma levels after dosing with test product under fasted and fed conditions
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
AUC0-inf - Comparison of the difference in plasma levels after dosing with test product under fasted and fed conditions
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
AUC0-t - Comparison of the difference in plasma levels after dosing with test product under fasted and fed conditions
Time Frame: Blood samples collected over 24 hour period
|
Blood samples collected over 24 hour period
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B006512
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on pravastatin
-
Akros Pharma Inc.CompletedType II HyperlipidemiaNetherlands
-
Daiichi Sankyo, Inc.CompletedHypercholesterolemiaUnited States
-
Pontificia Universidad Catolica de ChileBristol-Myers SquibbWithdrawn
-
Yonsei UniversityCompleted
-
National Center for Research Resources (NCRR)UnknownHeart DiseasesUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedPolycystic Kidney, Autosomal DominantUnited States
-
Arkansas Children's Hospital Research InstituteTerminatedEnd Stage Renal DiseaseUnited States
-
Bristol-Myers SquibbCompletedActue Coronary Syndromes
-
Mitsukoshi Health and Welfare FoundationDaiichi Sankyo Co., Ltd.; Ministry of Health, Labour and Welfare, JapanCompleted
-
Gachon University Gil Medical CenterCompleted